Cargando…

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients

BACKGROUND AND OBJECTIVES: Older adults are more susceptible to coronavirus disease 2019 (COVID-19). Interleukin-6 (IL-6) is an important cytokine in the cytokine release syndrome (CRS), and tocilizumab blocks the IL-6 receptor. The objective is to analyze the effect of tocilizumab on CRS in older p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Lengnan, Liu, Xin, Zhou, Yangwei, Liu, Aihua, Xu, Xiaomao, Wang, Xiaoxia, Zhong, Xuefeng, Qiao, Yu, Wen, Li, Xi, Huan, Mao, Yonghui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549770/ http://dx.doi.org/10.4103/imna.imna_5_22

Ejemplares similares

Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
por: Liu, Danfei, et al.
Publicado: (2020)

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
por: Price, Christina C., et al.
Publicado: (2020)

Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series
por: Yang, Stephen Su, et al.
Publicado: (2021)

Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
por: Klopfenstein, Timothée, et al.
Publicado: (2021)

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
por: de Cáceres, Carmen, et al.
Publicado: (2020)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Tripterygium wilfordii Hook F Treatment for Stage IV Diabetic Nephropathy: Protocol for a Prospective, Randomized Controlled Trial
por: Lengnan, Xu, et al.
Publicado: (2020)

The effects of aging on the renal function of a healthy population in Beijing and an evaluation of a range of estimation equations for glomerular filtration rate
por: Lengnan, Xu, et al.
Publicado: (2021)

Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
por: Xu, Lengnan, et al.
Publicado: (2023)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019
por: Melody, Megan, et al.
Publicado: (2020)

Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review
por: Jorgensen, Sarah C.J., et al.
Publicado: (2022)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Using Two Detection Methods to Observe the Changes and Significance of Free Light Chain in Serum and Urine in Patients with Renal Insufficiency
por: Xu, Lengnan, et al.
Publicado: (2022)

Demethylzeylasteral reduces the level of proteinuria in diabetic nephropathy: Screening of network pharmacology and verification by animal experiment
por: Xu, Lengnan, et al.
Publicado: (2022)

Coagulopathy in elderly patients with coronavirus disease 2019
por: Yuan, Xueting, et al.
Publicado: (2020)

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
por: Nasa, Prashant, et al.
Publicado: (2020)

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab
por: Morrison, Austin R., et al.
Publicado: (2020)

A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019
por: Lewis, Tyler C., et al.
Publicado: (2020)

Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
por: Hartog, Nicholas L., et al.
Publicado: (2021)

The relationship between sclerostin and carotid artery atherosclerosis in patients with stage 3–5 chronic kidney disease
por: Zhao, Ban, et al.
Publicado: (2020)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020)

Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome()
por: Velasco Puyó, Pablo, et al.
Publicado: (2020)

Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
por: Radbel, Jared, et al.
Publicado: (2020)

Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients
por: Sirimaturos, Michael, et al.
Publicado: (2020)

Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19)
por: Chen, Chong-xiang, et al.
Publicado: (2021)

Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab
por: Tabarsi, Payam, et al.
Publicado: (2021)

Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality
por: Sinha, Pranay, et al.
Publicado: (2021)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports
por: Abdullah, Shazia, et al.
Publicado: (2021)

Effect of Tocilizumab Treatment on Patients with Coronavirus Disease 2019 and Bacteremia: A Retrospective Cohort Study
por: Kuwahara, Masaatsu, et al.
Publicado: (2022)

Effect of tocilizumab treatment in mildly-obese patients with coronavirus disease 2019: a case series
por: Abe, Takashi, et al.
Publicado: (2022)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
por: Gao, Qian, et al.
Publicado: (2022)

The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia
por: Li, Hui, et al.
Publicado: (2020)

Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study
por: Kamran, Sultan Mehmood, et al.
Publicado: (2021)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study
por: Mastroianni, Antonio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ij01d83allcr3lgofoloue7rhg